- Policy
- Paxlovid and Dong-A’s Diosmin Powder were approved in July
- by Lee, Hye-Kyung Aug 7, 2023 05:23am
- The number of prescription drug approvals decreased significantly in July. The approvals, which had continuously increased from 70 in May to 93 in June, had fallen to record 29 in July. However, the drugs approved were nevertheless as significant as Pfizer Korea’s COVID-19 treatment ‘Paxlovid (nirmatrelvir, ritonavir)’, which had first bee
- Company
- Prescription of HA eye drops record KRW 166 bil in 1H
- by Kim, Jin-Gu Aug 7, 2023 05:23am
- The prescription market for hyaluronic acid eye drops grew to record the largest scale ever ahead of the reimbursement reevaluations set for the end of this year. In 1H alone, the market grew exceeded KRW 160 billion in prescriptions this year. The number of companies with half-year prescriptions that exceed KRW 10 billion increased fro
- Policy
- Sotyktu, the world's first TYK2I, received domestic approval
- by Lee, Hye-Kyung Aug 4, 2023 05:38am
- The Ministry of Food and Drug Safety (Minister Oh Yoo-Kyung) approved BMS Korea's new plaque psoriasis drug 'Sotyktu 6mg' on the 3rd. Psoriasis is a chronic skin disease caused by immune abnormalities, and plaque psoriasis is the most common form. Sotyktu treats psoriasis by selectively inhibiting 'tyrosine kinase-2 (TYK2)' receptors relat
- Policy
- Cancer immunotherapy Jemperli passes DREC review
- by Kim, Jung-Ju Aug 4, 2023 05:38am
- GSK Korea’s immno-oncology latecomer drug ‘Jemperli (dostarlimab)’ has passed its first step to reimbursement in Korea. On the other hand, Koselugo (selumetinib), AstraZeneca’s new drug for pediatric patients with neurofibromatosis type 1 (NF1), received a redicussion decision, warning of a bumpy journey ahead. The Health Insuranc
- Company
- Prescriptions of pseudoephedrine rise 35% in 1H
- by Chon, Seung-Hyun Aug 4, 2023 05:38am
- The prescription market for ‘pseudoephedrine,’ which continues to show an unstable supply and demand in the market, has expanded significantly. Despite the end of the pandemic, demand for the drug has increased significantly due to the increase in flu and cold patients. Accordingly, the need to raise the insurance price ceiling for the low-pri
- Company
- Antibiotic resistance is serious
- by Jung, Sae-Im Aug 4, 2023 05:37am
- Antibiotic resistance has been a global issue for several years. In 2016, the British government predicted that 700,000 people worldwide would die from antibiotic-resistant bacteria every year and that the death toll would reach 10 million by 2050 if no special measures were taken. In 2015, the World Health Organization (WHO) presented a 'global
- Policy
- Animal drugs can be manufactured at human drug factories
- by Kang, Shin-Kook Aug 3, 2023 05:35am
- The manufacture of veterinary drugs are now allowed at manufacturing facilities that manufacture human drugs. The Ministry of Agriculture, Food and Rural Affairs recently announced the legislation of an amendment to the ‘Decree on the Facility Standards for Veterinary Pharmacies and Manufacturers, Importers, and Retailers of Veterinary D
- Product
- Discontinued muscle painkillers in heavy demand
- by Kim JiEun Aug 3, 2023 05:35am
- The aftermath of some pharmaceutical companies’ tricking pharmacies into believing ‘there is not much stock available for order’ An ironic situation has occurred where a drug that pharmaceutical companies have given up manufacture and sales of due to the inability to demonstrate its effect is in heavy demand at pharmacies. On the 1st, i
- Company
- Variable for contract renewal for joint sales
- by Kim, Jin-Gu Aug 3, 2023 05:35am
- HK inno.N r, up 17% in about a year after the launch. HK inno.N sold alone, no commission share, profitability improved as more sold Expiration of the joint sales contract with Chong Kun Dang at the end of the year, will it affect renewal negotiations? HK inno.N K-Cab OD tablets accounted for 17.0% of the total prescription performanc
- Company
- Rise of 4-drug combos in hypertension/hyperlipidemia Tx mkt
- by Kim, Jin-Gu Aug 3, 2023 05:35am
- The growth of 3-drug combinations has slowed down in the hypertension/hyperlipidemia combination drug market. After recording double-digit YoY growth every quarter until the first half of last year, the spurt has slowed sharply since the end of last year. On the other hand, the 4-drug combinations that newly entered the market are rapidly exp
